William Blair Comments on Pyxis Oncology FY2027 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Research analysts at William Blair issued their FY2027 EPS estimates for shares of Pyxis Oncology in a research report issued on Tuesday, March 18th. William Blair analyst A. Hsieh expects that the company will earn ($1.27) per share for the year. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01.

A number of other research firms have also recently weighed in on PYXS. Royal Bank of Canada restated an “outperform” rating and issued a $8.00 price target on shares of Pyxis Oncology in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Pyxis Oncology in a report on Wednesday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Pyxis Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $9.20.

Pyxis Oncology Stock Performance

NASDAQ:PYXS opened at $1.07 on Thursday. Pyxis Oncology has a fifty-two week low of $0.99 and a fifty-two week high of $6.18. The stock has a market capitalization of $63.63 million, a P/E ratio of -1.04 and a beta of 1.11. The company’s 50-day simple moving average is $1.34 and its 200-day simple moving average is $2.39.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. purchased a new position in shares of Pyxis Oncology in the 3rd quarter valued at approximately $1,405,000. Geode Capital Management LLC raised its position in shares of Pyxis Oncology by 5.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock valued at $3,982,000 after purchasing an additional 57,016 shares during the last quarter. Barclays PLC raised its position in shares of Pyxis Oncology by 275.0% in the 3rd quarter. Barclays PLC now owns 64,089 shares of the company’s stock valued at $235,000 after purchasing an additional 46,997 shares during the last quarter. State Street Corp raised its position in shares of Pyxis Oncology by 28.0% in the 3rd quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after purchasing an additional 208,344 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of Pyxis Oncology by 40.8% in the 3rd quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock valued at $182,000 after purchasing an additional 14,349 shares during the last quarter. 39.09% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.